Hyderabad, Feb 10 (.) Syngene International on Tuesday announced a strategic collaboration with Johns Hopkins University to accelerate early-stage drug discovery programs and platform technologies emerging from the university’s research laboratories.
The collaboration is anchored in Syngene’s SynVent platform, a fully integrated drug discovery and development engine covering discovery biology, medicinal and synthetic chemistry, DMPK (drug metabolism and pharmacokinetics), toxicology, and early development.
The initiative will also leverage Syngene’s Connector model, which is designed to link high-potential academic research with strategic investors, pharmaceutical partners, and downstream licensing opportunities, the company said in a release here.
Under the partnership, promising discoveries originating from Johns Hopkins laboratories will be advanced through Syngene’s industrial-scale drug discovery capabilities, with a focus on compressing development timelines and improving the probability of successful clinical translation.
Kenneth Barr, Senior Vice President and Head of Strategic Collaborations at Syngene International, said the collaboration underscores the company’s commitment to expanding its global innovation ecosystem.
“By combining pioneering academic science with our integrated discovery and development capabilities, we aim to significantly reduce the time it takes for high-potential programs to become clinically relevant, creating a faster and more efficient pipeline of new medicines,” he said.
Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, said the partnership could connect Johns Hopkins discoveries with Syngene’s drug discovery expertise, along with pharmaceutical, biotech, and investor networks, ultimately accelerating the path from laboratory science to potential patient solutions. . KNR .